In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Predictors of combined critical endpoint (all-cause death/heart failure hospitalization) in patients with chronic heart failure and reduced left ventricular ejection fraction.
1NSC Institute of Cardiology M.D. Strazhesko, department of heart failure - Kiev - Ukraine
Background. It is known that patients with heart failure (HF) demonstrate high mortality/hospitalization rate. So, the search of clinical and laboratory predictors of combined endpoint (death or HF hospitalization) potentially may improve the estimation of their individual prognosis.
Objective. To establish the predictors of all-cause death/HF hospitalization during 2 – year follow-up in patients with chronic heart failure (CHF) and redused (red) left ventricular ejection fraction (LVEF).
Methods. 134 stable CHF pts (NYHA II-IV, LVEF < 40%) under optimized standard treatment were examined. Statistics programs package SPSS 13,0 was used; cluster analysis and logistic regression were used to calculate the predictors. Conclusion. Plasma levels of bilirubin, ALT, BUN, NTproBNP, and citrullin as well as LVEF, SBP, BMI, GFR, FMVR and MHFLQ score are the strong predictors of critical event (death or HF hospitalization) in CHF with redLVEF.
Cut off level
GFR, ml/min/1,73 m2
SBP, mm Hg
SBP – systolic blood pressure; MHFLQ – Minnesota HF life questionnaire, BUN – blood urea nitrogen, ALT - alaninaminotransferase, BMI - body mass index, GFR – glomerular filtration rate, FMVR – flow-mediated vasodilatory response.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease